Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $30.00.

A number of brokerages have recently commented on ATXS. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday, June 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $47.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th.

Astria Therapeutics Price Performance

Astria Therapeutics stock traded down $0.10 during mid-day trading on Monday, hitting $6.67. 276,814 shares of the company were exchanged, compared to its average volume of 358,366. The business's 50 day simple moving average is $5.14 and its two-hundred day simple moving average is $6.06. The company has a market capitalization of $376.39 million, a P/E ratio of -3.57 and a beta of 0.41. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Equities research analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its holdings in Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock valued at $556,000 after acquiring an additional 1,381 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Astria Therapeutics by 9.0% during the fourth quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company's stock worth $170,000 after purchasing an additional 1,587 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Astria Therapeutics by 7.6% during the fourth quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 2,222 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Astria Therapeutics by 109.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Astria Therapeutics by 19.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock worth $159,000 after purchasing an additional 2,878 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.